Noven Pharmaceuticals Inc. (NOVN) Earns Milestone Payment Under P&G Pharmaceuticals, Inc. (PG) Collaboration 
10/19/2005 5:10:53 PM

MIAMI--(BUSINESS WIRE)--Dec. 29, 2004--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that it has earned a $3.0 million success fee for attaining a development milestone under its development collaboration with P&G Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company. Noven expects to report the $3.0 million success fee as license and contract revenues for the quarter ending December 31, 2004.